(ANSA) – ROME, FEBRUARY 25 – The new anti Sars-CoV-2 Evusheld intramuscular monoclonal antibody (composed of tixagevimab and cilgavimab) is now available. From Monday the administrations will begin at Spallanzani, to give protection to these fragile people currently not protected by vaccination. This is what we learn from the direction of Spallanzani. “The drug is indicated in the primary prophylaxis of immunosuppressed people unresponsive to Covid vaccines – he explains -. Studies indicate that the clinical efficacy of Evusheld is close to 80% in the prevention of symptomatic disease. This new monoclonal represents a further innovative tool that goes alongside third dose vaccination, to effectively counter this phase of the pandemic “. (HANDLE).
Source: Ansa
I have been working in the news industry for over 10 years now and I have worked for some of the biggest news websites in the world. My focus has always been on entertainment news, but I also cover a range of other topics. I am currently an author at Global happenings and I love writing about all things pop-culture related.
